CDY 1.43% 7.1¢ cellmid limited

[ATTACH] The above part of the symposium announcement from May...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 458 Posts.
    lightbulb Created with Sketch. 130
    Glycosaminoglycans-Sevilla.png

    The above part of the symposium announcement from May 2018 (the subject of this thread) refers to Dr Pedro Nieto, who had also contributed to the 2016 Midkine Symposium. See here: http://www.cellmid.com.au/content_common/pg-pedro-nieto-mk-symposium-2016.seo or click on the thumbnail:
    nietopedrocellmidciccartujasevilla.png   

    It seems to me that research into a better understanding of Mdikine biology is being intensified by Dr Nieto at University of Seville. They seem to be hiring a scientist for a project at their research centre cicCartuja, in particular the Glycosystems Laboratory.

    Project Description:
    gag-Glycosaminoglycans-Sevilla-pedronieto-cellmid-mk-ptn-midkine.png
    Download link: https://eshorizonte2020.es/expressions/pdf/52649

    "This interaction is at the origin of their function but also is at pathological processes as tumorigenesis, angiogenesis. We have already detected and performed a preliminary analysis of the interactions between MK or PTN and CS derivatives. From this project a progress into the comprehension of the molecular basis of their activity is expected."

    What exactly that means is beyond my knowledge but research in this area is obviously being pursued further.
 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.